Comparison of five-year clinical efficacy of simultaneous pancreas-kidney transplantation in the treatment of type 1 and type 2 diabetes mellitus with end-stage renal disease
10.3760/cma.j.cn.115807-20230813-00056
- VernacularTitle:胰肾联合移植治疗1型和2型糖尿病合并终末期肾病的五年临床疗效比较
- Author:
Limin ZHANG
1
;
Xia LU
;
Chen DAI
;
Changsheng MING
;
Nianqiao GONG
Author Information
1. 华中科技大学同济医学院附属同济医院器官移植研究所，器官移植教育部重点实验室，国家卫生健康委员会器官移植重点实验室，中国医学科学院器官移植重点实验室，武汉 430030
- Keywords:
Simultaneous pancreas-kidney transplantation;
Type 1 diabetes mellitus;
Type 2 diabetes mellitus;
End-stage renal disease
- From:
Chinese Journal of Endocrine Surgery
2023;17(6):645-649
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the long-term clinical efficacy of simultaneous pancreas-kidney transplantation (SPK) in the treatment of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) with end-stage renal disease (ESRD) , and to explore whether T2DM with ESRD can be an indication for SPK.Methods:A total of 62 cases of SPK performed in our center were retrospectively analyzed. Based on the same baseline principle, the patients were divided into T1DM group (30 cases) and T2DM (32 cases) according to the primary disease of diabetes.Results:There was no significant difference in male gender, preoperative hemoglobin or HbA1c between the two groups. Compared with T2DM group, both of the age at surgery [ (31.8±5.2) years vs (49.5±5.7) years, P<0.001] and body mass index [ (21.8±1.3) kg/m 2 vs (25.0±3.8) kg/m 2, P<0.001] were lower in T1DM group. Compared with T2DM, the insulin dosage in the T1DM was higher, and there was no C-peptide release, and the difference was statistically significant. The patients were followed up for 5 years. There were no significant differences in fasting blood glucose, HbA1c, C-peptide, serum creatinine or eGFR between the two groups at 1, 3 and 5 years after surgery. The incidence of pulmonary infection, BK virus infection and acute rejection of transplanted kidney in T1DM group was lower than that in T2DM group, but the difference was not statistically significant. At 1 and 3 years after transplantation, the survival rates of recipients, transplanted pancreas and kidneys were 100% in both groups. In the 5th year, one patient in T2DM group died of acute myocardial infarction at 48 months after surgery, but the renal and pancreatic grafts functioned well. The survival rate of recipients in T1DM group (100%) was higher than that in T2DM group (96.9%) on 5 years after surgery ( P=0.333) , but the difference was not statistically significant. After excluding the deceased recipients, the transplanted pancreas and kidneys in both groups survived. Conclusions:There is no significant difference in the short and long-term clinical outcomes between patients with T2DM and ESRD who received SPK and those with T1DM and ESRD. T2DM with ESRD can be an indication for SPK, but a large sample size study is still needed to further improve the selection criteria.
